Allowing drug innovation to "seamlessly interface" with market demand

"The country's existing more than 5000 pharmaceutical companies have not yet entered the world's top 50 pharmaceutical companies Even from a generics perspective, Chinese pharmaceutical companies are far from the likes of Israel teva and German andoz "In a recent corporate interview, Dr Liu Hongli, general manager of Shanghai Hepu Biotech Co., Ltd., was worried China's current annual approval of drugs, 90% of the dosage modification and generic drugs, the main reason lies in innovation
drug research and development investment, research and development cycle is long, the vast number of pharmaceutical companies or hope, or do not want to take risks for this In the only 10 per cent of the innovation
drug research and development enterprises, some enterprises because of the market demand, the variety research and development process did not form a capitalized commercial development model, resulting in most of the innovative varieties can not be effectively industrialization and eventually died Drawing on the commercial development model of the capitalization of the international new drug research and development process, aiming at the market demand for differentiated medicines in China, and making new drug research and development, drug market and capital market seamless docking, it is becoming the development direction of a group of Zhangjiang Pharmaceutical Valley enterprises such as Shanghai Hepu Biotech Co., Ltd ("Shanghai Hepu") Chronic hepatitis B virus (hbv) infection is one of the most serious health problems in China China's existing hbv long-term carrier 87 million, chronic hepatitis B patients 20 million, the annual increase of more than 1.5 million cases of chronic hepatitis B The huge medical need for liver disease has made our country the world's largest market for liver medicine Hepatitis B and its related liver disease sit in Europe and the United States relatively rare, major Western pharmaceutical companies on the research and development of new drugs for hepatitis B is very limited, self-reliance research and development of new hepatitis B drugs is the only way to solve the problem of liver disease treatment in China, but also for China's research and development of pharmaceutical enterprises extremely rarely retain a relatively broad market, competition is not yet fierce development space Long-term original drug research and development, Shanghai Hepu developed a "focus on hepatitis B-related diseases innovative drug research and development to achieve enterprise growth, and gradually intervene in the mainstream market new drug research and development to complete the enterprise growth" development strategy, and for this purpose, including Heprapeptide and Hepu infenfen, including highly competitive hepatitis B-related diseases new drug varieties research and development line Among them, The Herprapeptide is a new mechanism hepatitis B treatment drug, by binding to hbv infection receptor, to protect healthy liver cells from hepatitis B virus reinfection, infected with the virus liver cells under the role of the immune system gradually destroyed to clear, for chronic hepatitis B provides a new treatment strategy The project has been "major new drug creation" national science and technology major projects, in 2014 will be in accordance with the country's 1.1 types of innovative chemicals into the clinical trial research stage Hepuinfen is the third generation interferon after common interferon and long-acting interferon, targeting interferon to the liver, the main organ of hepatitis B virus replication, through a specific guiding structure While reducing interferon's extra-hepatic toxicity, it is hoped that the current problem between interferon efficacy and toxicity can be solved by effectively increasing the concentration of drugs in the liver The project has been established by the National Science and Technology SME Innovation Fund Innovative drug research and development cycle is often as long as 10 years, requires a huge amount of research and development funds long-term and sustained investment, product listing is the end of technological innovation General Manager Dr Liu Hongli said that innovative drug research and development is a double dance of technology and capital, technological innovation and capital driven are indispensable, and the state's support for innovative drug research and development has achieved a broad stage for innovative drug research and development As early as the first research and development project of Shanghai Hepu, Heple on the technology research and development, Shanghai Hepu has maintained a high degree of business sensitivity, technology research and development and business plans to keep pace, while closely paying close attention to the relevant state support policies In 2010, Shanghai Hepu declared the "major new drug creation" national science and technology major special project with the results of the hepra peptide pilot research, and obtained 5 million yuan of research and development funds from the Ministry of Science and Technology and Zhangjiang Park in Shanghai, providing key support for the follow-up preclinical research of the project After completing the clinical research declaration of the Heprapeptide project in 2012, Shanghai Hepu made extensive contacts with the investment capital in the pharmaceutical field, and finally obtained 25 million yuan investment from the Shanghai Pudong Biopharmaceutical Industry Development Fund for the project General Manager Dr Liu Hongli stressed that the development of new drug projects must be consistent with the increase in capital gains, to form a mutually beneficial and win-win situation, new drug research and development will be able to reach the end Take the Hepra peptide project as an example, preclinical research and development investment of about 10 million yuan, into the clinical research phase after the project value of 50 million yuan, the upfront investment value of 400%; The market and the value of the project are directly related to the new drug, and Dr Liu Hongli has a clear understanding of the company at the beginning of its existence Through the huge market mapping of the value of new drug research and development projects, project development to drive capital appreciation, through capital appreciation effect to drive more research and development capital investment, and ultimately achieve technological innovation, market and capital win-win ecology How innovative products are more effective in marketing is testing the wisdom of entrepreneurs With the increasing difficulty of drug research and development and the continuous expansion of drug technology, the development of research and development drug companies will face serious challenges "The development of Hep Bio's Herprapeptide, Hepinfen and subsequent new drugs will form a strategic market support point in the field of hepatitis B treatment Liu Hongli said At present, Shanghai Hepu's main market is mainly China, follow-up projects will gradually transition from local innovation to international development, the first patent promotion countries will be India and Indonesia and other countries with large populations and hepatitis B infection rate is equally high In the field of research, there will also be attempts to expand into liver tumor and hepatitis C treatment (Responsible Editor: yf001)